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Mitochondrial metabolism controls immune cell function, but comprehensive tools to assess 
human primary immune cell metabolic functions in disease are lacking. We have previously 
demonstrated that CD19+ B cells are more glycolytic than CD4+ T cells, and that both PBMCs 
and CD4+ T cells from subjects with type 2 diabetes (T2D) are more glycolytic than their 
counterpart from BMI-matched non-diabetic controls (ND). However, the contribution of 
mitochondrial mass to these metabolic phenotypes is untested. Generally, effector CD4+ T cells 
are glycolytic, whereas regulatory T cells and memory CD8+ T cells rely more on fatty acid 
oxidation. To assess the contribution of immune cell skewing and mitochondrial mass to the 
enhanced glycolytic capacity of PBMCs from T2D and resting B cells, we designed a 14-color 
panel based on common lineage markers and chemokine receptor patterns, in lieu of intracellular 
cytokine staining, including MitoTracker Green to phenotype 63 total samples from ND subjects, 
subjects with pre-diabetes, and subjects with T2D. Our samples were run in 5 batches on a BD 
FACSARIA II SORP. Pre-established panel-specific PMT voltages were tracked using 6-peak 
Ultrarainbow beads. To normalize MitoTracker Green fluorescence intensity that could vary due 
to batch effects, each batch included a reference donor PBMC sample that was frozen in multiple 
aliquots from the same blood draw. With this approach, we could quantify the putative 
percentages of immune cell populations (CD19+ B cells, CD8+ naïve and memory/effector T 
cells, CD4+ cells including Tregs and populations enriched in Th1, Th2 and Th17) and the 
relative mitochondrial mass among these subsets. We found that CD19+ B cells in PBMCs from 
both ND and T2D subjects had significantly less mitochondrial mass than CD4+ cells. This 
reduced mitochondrial mass may potentially explain B cells greater usage of glycolysis 
compared to CD4+ T cells.  Of all the CD4+ T cell subsets, Th17 cell consistently had the least 
amount of mitochondrial mass, potentially indicating that these cells are more dependent on 
glucose than previously appreciated. Our results validate the rigor of our 14-color panel approach 
to phenotype T cells subsets and quantify relative mitochondrial mass as well as provide a tool to 
further explore metabolism in human primary cells and disease.  
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